NKGen Biotech announces new funding to regain compliance with reporting obligations and listing standards

6 hours ago 1

NKGen Biotech (OTC:NKGN) announced that it has raised $2 million in new capital from a Japanese strategic investor to regain compliance with reporting obligations and listing standards.
The investor will help NKGen bring its novel NK cell therapy, troculeucel, autologous expanded NK cell

Recommended For You